首页 > 最新文献

Biochemical pharmacology最新文献

英文 中文
SERPINA1 promotes the invasion, metastasis, and proliferation of pancreatic ductal adenocarcinoma via the PI3K/Akt/NF-κB pathway SERPINA1通过PI3K/Akt/NF-κB途径促进胰腺导管腺癌的侵袭、转移和增殖。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-18 DOI: 10.1016/j.bcp.2024.116580
Chen Xiubing , Li Huazhen , Wei Xueyan , Ning Jing , Li Qing , Jiang Haixing , Qin Shanyu , Lu Jiefu
Serpin peptidase inhibitor clade A member 1 (SERPINA1) is highly expressed in a variety of solid tumors. However, its role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. Here, we report evidence that SERPINA1 acts as a potent oncogene to drive its extremely malignant character. We found that elevated SERPINA1 expression in primary tumors was associated with lymph node metastasis and shorter survival in PDAC patients. Mechanistic investigations revealed that overexpression of SERPINA1 induced nuclear translocation and phosphorylation of the p65 subunit through the PI3K/Akt/NF-κB pathway, thereby promoting the invasion, metastasis and proliferation of PDAC cells in vitro and in vivo. Conversely, the knockdown of SERPINA1 attenuated this signaling pathway and restored the phenotype of PDAC cells overexpressing SERPINA1. Overall, our study reveals that SERPINA1 affects the properties of PDAC through the PI3K/Akt/NF-κB pathway, and its activation confers the clinical features of epithelial-mesenchymal transition and proliferation in the disease.
血清素肽酶抑制剂 A 族成员 1(SERPINA1)在多种实体瘤中高度表达。然而,它在胰腺导管腺癌(PDAC)中的作用仍不清楚。在此,我们报告了 SERPINA1 作为一种强效致癌基因驱动胰腺导管腺癌极度恶性的证据。我们发现,原发性肿瘤中 SERPINA1 表达的升高与淋巴结转移和 PDAC 患者的生存期缩短有关。机理研究发现,SERPINA1 的过表达可通过 PI3K/Akt/NF-κB 通路诱导 p65 亚基的核转位和磷酸化,从而促进 PDAC 细胞在体外和体内的侵袭、转移和增殖。相反,敲除 SERPINA1 可减轻这一信号通路,并恢复过表达 SERPINA1 的 PDAC 细胞的表型。总之,我们的研究揭示了SERPINA1通过PI3K/Akt/NF-κB途径影响PDAC的特性,其激活赋予了该疾病上皮-间质转化和增殖的临床特征。
{"title":"SERPINA1 promotes the invasion, metastasis, and proliferation of pancreatic ductal adenocarcinoma via the PI3K/Akt/NF-κB pathway","authors":"Chen Xiubing ,&nbsp;Li Huazhen ,&nbsp;Wei Xueyan ,&nbsp;Ning Jing ,&nbsp;Li Qing ,&nbsp;Jiang Haixing ,&nbsp;Qin Shanyu ,&nbsp;Lu Jiefu","doi":"10.1016/j.bcp.2024.116580","DOIUrl":"10.1016/j.bcp.2024.116580","url":null,"abstract":"<div><div>Serpin peptidase inhibitor clade A member 1 (SERPINA1) is highly expressed in a variety of solid tumors. However, its role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. Here, we report evidence that SERPINA1 acts as a potent oncogene to drive its extremely malignant character. We found that elevated SERPINA1 expression in primary tumors was associated with lymph node metastasis and shorter survival in PDAC patients. Mechanistic investigations revealed that overexpression of SERPINA1 induced nuclear translocation and phosphorylation of the p65 subunit through the PI3K/Akt/NF-κB pathway, thereby promoting the invasion, metastasis and proliferation of PDAC cells <em>in vitro</em> and <em>in vivo</em>. Conversely, the knockdown of SERPINA1 attenuated this signaling pathway and restored the phenotype of PDAC cells overexpressing SERPINA1. Overall, our study reveals that SERPINA1 affects the properties of PDAC through the PI3K/Akt/NF-κB pathway, and its activation confers the clinical features of epithelial-mesenchymal transition and proliferation in the disease.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116580"},"PeriodicalIF":5.3,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction notice to “Hemiprotonic ph-ph+ with two targets inhibits metastatic breast cancer and concurrent candidiasis” [Biochem. Pharmacol. 226 (2024) 116394] 具有两个靶点的半质子 ph-ph+ 抑制转移性乳腺癌和并发念珠菌病》[Biochem. Pharmacol. 226 (2024) 116394]的撤稿通知。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-17 DOI: 10.1016/j.bcp.2024.116568
Jingli Li, Zizhen Zhao, Dongmei You, Yafang Xie, Yixiao Feng, Xiaorong Li, Zhihong Cui, Ailing Fu
{"title":"Retraction notice to “Hemiprotonic ph-ph+ with two targets inhibits metastatic breast cancer and concurrent candidiasis” [Biochem. Pharmacol. 226 (2024) 116394]","authors":"Jingli Li,&nbsp;Zizhen Zhao,&nbsp;Dongmei You,&nbsp;Yafang Xie,&nbsp;Yixiao Feng,&nbsp;Xiaorong Li,&nbsp;Zhihong Cui,&nbsp;Ailing Fu","doi":"10.1016/j.bcp.2024.116568","DOIUrl":"10.1016/j.bcp.2024.116568","url":null,"abstract":"","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"229 ","pages":"Article 116568"},"PeriodicalIF":5.3,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction 在大鼠射血分数保留型心力衰竭模型中使用沙库比妥/缬沙坦对心脏代谢的影响
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-16 DOI: 10.1016/j.bcp.2024.116571
Sandra Moraña-Fernández , Xocas Vázquez-Abuín , Alana Aragón-Herrera , Laura Anido-Varela , Javier García-Seara , Óscar Otero-García , Diego Rodríguez-Penas , Manuel Campos-Toimil , Manuel Otero-Santiago , Alexandre Rodrigues , Alexandre Gonçalves , Juliana Pereira Morais , Inês N. Alves , Cláudia Sousa-Mendes , Inês Falcão-Pires , José Ramón González-Juanatey , Sandra Feijóo-Bandín , Francisca Lago
The promising results obtained in the PARADIGM-HF trial prompted the approval of sacubitril/valsartan (SAC/VAL) as a first-in-class treatment for heart failure with reduced ejection fraction (HFrEF) patients. The effect of SAC/VAL treatment was also studied in patients with heart failure with preserved ejection fraction (HFpEF) and, although improvements in New York Heart Association (NYHA) class, HF hospitalizations, and cardiovascular deaths were observed, these results were not so promising. However, the demand for HFpEF therapies led to the approval of SAC/VAL as an alternative treatment, although further studies are needed. We aimed to elucidate the effects of a 9-week SAC/VAL treatment in cardiac function and metabolism using a preclinical model of HFpEF, the Zucker Fatty and Spontaneously Hypertensive (ZSF1) rats. We found that SAC/VAL significantly improved diastolic function parameters and modulated respiratory quotient during exercise. Ex-vivo studies showed that SAC/VAL treatment significantly decreased heart, liver, spleen, and visceral fat weights; cardiac hypertrophy and percentage of fibrosis; lipid infiltration in liver and circulating levels of cholesterol and sodium. Moreover, SAC/VAL reduced glycerophospholipids, cholesterol, and cholesteryl esters while increasing triglyceride levels in cardiac tissue. In conclusion, SAC/VAL treatment improved diastolic and hepatic function, respiratory metabolism, reduced hypercholesterolemia and cardiac fibrosis and hypertrophy, and was able to modulate cardiac metabolic profile. Our findings might provide further insight into the therapeutic benefits of SAC/VAL treatment in obese patients with HFpEF.
PARADIGM-HF 试验取得的良好结果促使萨库比特利/缬沙坦(SAC/VAL)作为射血分数降低型心力衰竭(HFrEF)患者的首选治疗药物获得批准。此外,还对射血分数保留型心力衰竭(HFpEF)患者进行了 SAC/VAL 治疗效果的研究,虽然观察到纽约心脏协会(NYHA)分级、心力衰竭住院率和心血管死亡人数有所改善,但这些结果并不令人乐观。然而,由于对高频心衰疗法的需求,SAC/VAL 作为一种替代治疗方法获得了批准,尽管还需要进一步的研究。我们的目的是利用高频心衰的临床前模型--扎克脂肪和自发性高血压(ZSF1)大鼠,阐明为期 9 周的 SAC/VAL 治疗对心脏功能和代谢的影响。我们发现,SAC/VAL 能明显改善舒张功能参数,并调节运动时的呼吸商。体内外研究显示,SAC/VAL 治疗可显著降低心脏、肝脏、脾脏和内脏脂肪重量;心脏肥大和纤维化百分比;肝脏脂质浸润以及循环中胆固醇和钠的水平。此外,SAC/VAL 还能降低甘油磷脂、胆固醇和胆固醇酯,同时提高心脏组织中甘油三酯的水平。总之,SAC/VAL 治疗可改善舒张功能和肝功能、呼吸代谢、降低高胆固醇血症、心脏纤维化和肥大,并能调节心脏代谢轮廓。我们的研究结果或许能进一步揭示 SAC/VAL 治疗对肥胖高频心衰患者的疗效。
{"title":"Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction","authors":"Sandra Moraña-Fernández ,&nbsp;Xocas Vázquez-Abuín ,&nbsp;Alana Aragón-Herrera ,&nbsp;Laura Anido-Varela ,&nbsp;Javier García-Seara ,&nbsp;Óscar Otero-García ,&nbsp;Diego Rodríguez-Penas ,&nbsp;Manuel Campos-Toimil ,&nbsp;Manuel Otero-Santiago ,&nbsp;Alexandre Rodrigues ,&nbsp;Alexandre Gonçalves ,&nbsp;Juliana Pereira Morais ,&nbsp;Inês N. Alves ,&nbsp;Cláudia Sousa-Mendes ,&nbsp;Inês Falcão-Pires ,&nbsp;José Ramón González-Juanatey ,&nbsp;Sandra Feijóo-Bandín ,&nbsp;Francisca Lago","doi":"10.1016/j.bcp.2024.116571","DOIUrl":"10.1016/j.bcp.2024.116571","url":null,"abstract":"<div><div>The promising results obtained in the PARADIGM-HF trial prompted the approval of sacubitril/valsartan (SAC/VAL) as a first-in-class treatment for heart failure with reduced ejection fraction (HFrEF) patients. The effect of SAC/VAL treatment was also studied in patients with heart failure with preserved ejection fraction (HFpEF) and, although improvements in New York Heart Association (NYHA) class, HF hospitalizations, and cardiovascular deaths were observed, these results were not so promising. However, the demand for HFpEF therapies led to the approval of SAC/VAL as an alternative treatment, although further studies are needed. We aimed to elucidate the effects of a 9-week SAC/VAL treatment in cardiac function and metabolism using a preclinical model of HFpEF, the Zucker Fatty and Spontaneously Hypertensive (ZSF1) rats. We found that SAC/VAL significantly improved diastolic function parameters and modulated respiratory quotient during exercise. <em>Ex-vivo</em> studies showed that SAC/VAL treatment significantly decreased heart, liver, spleen, and visceral fat weights; cardiac hypertrophy and percentage of fibrosis; lipid infiltration in liver and circulating levels of cholesterol and sodium. Moreover, SAC/VAL reduced glycerophospholipids, cholesterol, and cholesteryl esters while increasing triglyceride levels in cardiac tissue. In conclusion, SAC/VAL treatment improved diastolic and hepatic function, respiratory metabolism, reduced hypercholesterolemia and cardiac fibrosis and hypertrophy, and was able to modulate cardiac metabolic profile. Our findings might provide further insight into the therapeutic benefits of SAC/VAL treatment in obese patients with HFpEF.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116571"},"PeriodicalIF":5.3,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological functions of the m6A reader YTHDF2 and its role in central nervous system disorders m6A 阅读器 YTHDF2 的生物功能及其在中枢神经系统疾病中的作用。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-16 DOI: 10.1016/j.bcp.2024.116576
Lili Song , Huimin Liu , Weiyu Yang , Hongqing Yin , Jiayi Wang , Maojuan Guo , Zhen Yang
N6-methyladenosine (m6A) is a prevalent mRNA modification in eukaryotic cells, characterized by its reversible nature. YTH structural domain family protein 2 (YTHDF2), a key reader of m6A, plays a crucial role in identifying and binding m6A-containing RNAs, thereby influencing RNA metabolism through various functional mechanisms. The upstream and downstream targets of YTHDF2 are critical in the pathogenesis of various central nervous system (CNS) diseases, affecting disease development by regulating signaling pathways and gene expression. This paper provides an overview of current research on the role of YTHDF2 in CNS diseases and investigates the regulatory mechanisms by which YTHDF2 influences the development of these conditions. This exploration aims to improve understanding of disease pathogenesis and offer novel insights for the targeted prevention and treatment of neurological disorders.
N6-甲基腺苷(m6A)是真核细胞中普遍存在的一种mRNA修饰,具有可逆性。YTH 结构域家族蛋白 2(YTHDF2)是 m6A 的关键阅读器,在识别和结合含 m6A 的 RNA 方面发挥着关键作用,从而通过各种功能机制影响 RNA 代谢。YTHDF2 的上游和下游靶标在各种中枢神经系统(CNS)疾病的发病机制中至关重要,它们通过调节信号通路和基因表达影响疾病的发展。本文概述了目前有关 YTHDF2 在中枢神经系统疾病中作用的研究,并探讨了 YTHDF2 影响这些疾病发展的调控机制。这一探索旨在提高人们对疾病发病机制的认识,并为有针对性地预防和治疗神经系统疾病提供新的见解。
{"title":"Biological functions of the m6A reader YTHDF2 and its role in central nervous system disorders","authors":"Lili Song ,&nbsp;Huimin Liu ,&nbsp;Weiyu Yang ,&nbsp;Hongqing Yin ,&nbsp;Jiayi Wang ,&nbsp;Maojuan Guo ,&nbsp;Zhen Yang","doi":"10.1016/j.bcp.2024.116576","DOIUrl":"10.1016/j.bcp.2024.116576","url":null,"abstract":"<div><div>N6-methyladenosine (m6A) is a prevalent mRNA modification in eukaryotic cells, characterized by its reversible nature. YTH structural domain family protein 2 (YTHDF2), a key reader of m6A, plays a crucial role in identifying and binding m6A-containing RNAs, thereby influencing RNA metabolism through various functional mechanisms. The upstream and downstream targets of YTHDF2 are critical in the pathogenesis of various central nervous system (CNS) diseases, affecting disease development by regulating signaling pathways and gene expression. This paper provides an overview of current research on the role of YTHDF2 in CNS diseases and investigates the regulatory mechanisms by which YTHDF2 influences the development of these conditions. This exploration aims to improve understanding of disease pathogenesis and offer novel insights for the targeted prevention and treatment of neurological disorders.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116576"},"PeriodicalIF":5.3,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carvedilol through ß1-Adrenoceptor blockade ameliorates glomerulonephritis via inhibition of oxidative stress, apoptosis, autophagy, ferroptosis, endoplasmic reticulum stress and inflammation 卡维地洛通过阻断ß1-肾上腺素受体,抑制氧化应激、细胞凋亡、自噬、铁蛋白沉积、内质网应激和炎症,从而改善肾小球肾炎。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-12 DOI: 10.1016/j.bcp.2024.116570
Wei-Yu Lin , Yu-Hsuan Cheng , Pei-Yu Liu , Shih-Ping Hsu , San-Chi Lin , Chiang-Ting Chien
Glomerulonephritis (GN) is one of the main causes of end stage renal disease and requires an effective treatment for inhibiting GN. Renal nerves through efferent (RENA) and afferent (RANA) innervation to glomeruli regulate the glomerular function. We delineated the role of RENA and RANA on anti-Thy1.1-induced GN. Female Wistar rats were divided into Control, Thy1.1 plus anti-Thy1.1, bilaterally renal nerve denervation (DNX) plus anti-Thy1.1, and topical capsaicin to bilateral renal nerves for selective ablation of RANA (DNAX) plus anti-Thy1.1. We examined RANA and RENA response to anti-Thy1.1 and compared the effect of DNX or DNAX on urinary oxidative stress, renal gp91, tyrosine hydroxylase (TH), calcitonin gene-related peptide (CGRP), apoptosis, autophagy, ferroptosis, antioxidant enzymes, endoplasmic reticulum (ER) stress and inflammation by western blot. Anti-Thy1.1 significantly enhanced RENA, but did not affect RANA. DNX significantly decreased TH and CGRP expression, whereas DNAX only reduced CGRP expression. Anti-Thy1.1 significantly increased glomerulosclerosis injury, urinary protein, electron paramagnetic resonance signals of alpha-(4-pyridyl-N-oxide)-N-tert-butylnitrone adducts, 8-isoprostane and nitrotyrosine levels, NADPH oxidase gp91phox (gp91), macrophage/monocyte (ED-1), GRP-78, Beclin-1/LC3-II, Bax/caspase-3/poly(ADP-ribose) polymerase expression, inflammatory cytokines levels and decreased renal Copper/Zinc superoxide dismutase, Cystine/glutamate transporter (xCT) and Glutathione peroxidase 4 (GPX4) expression vs. Control. The enhanced oxidative parameters or reduced antioxidant defense by anti-Thy1.1 were significantly attenuated by DNX but not DNAX. Additionally, oral ß1-adrenoceptor antagonist-Carvedilol at an early stage reduced anti-Thy1.1 increased proteinuria level and oxidative parameters. Our data suggest that DNX and ß1-adrenoceptor antagonist-Carvedilol efficiently attenuate oxidative stress, inflammation, ER stress, autophagy, ferroptosis and apoptosis in GN.
肾小球肾炎(GN)是导致终末期肾病的主要原因之一,需要有效的治疗方法来抑制 GN。肾脏神经通过传出神经(RENA)和传入神经(RANA)支配肾小球,调节肾小球功能。我们研究了 RENA 和 RANA 在抗 Thy1.1 诱导的 GN 中的作用。雌性 Wistar 大鼠被分为对照组、Thy1.1 加抗-Thy1.1 组、双侧肾神经去神经支配组(DNX)加抗-Thy1.1 组和双侧肾神经局部辣椒素选择性消融 RANA 组(DNAX)加抗-Thy1.1 组。我们检测了RANA和RENA对抗Thy1.1的反应,并通过Western印迹比较了DNX或DNAX对尿氧化应激、肾gp91、酪氨酸羟化酶(TH)、降钙素基因相关肽(CGRP)、细胞凋亡、自噬、铁蛋白沉积、抗氧化酶、内质网(ER)应激和炎症的影响。抗Thy1.1能显著增强RENA,但不影响RANA。DNX 能明显降低 TH 和 CGRP 的表达,而 DNAX 只能降低 CGRP 的表达。抗Thy1.GRP-78、Beclin-1/LC3-II、Bax/caspase-3/聚(ADP-核糖)聚合酶的表达、炎症细胞因子水平以及肾脏铜/锌超氧化物歧化酶、胱氨酸/谷氨酸转运体(xCT)和谷胱甘肽过氧化物酶 4(GPX4)的表达与对照组相比均有所下降。对照组。抗-Thy1.1增强的氧化参数或降低的抗氧化防御能力被DNX而非DNAX显著减弱。此外,早期口服ß1-肾上腺素受体拮抗剂-卡维地洛(Carvedilol)可降低抗-Thy1.1导致的蛋白尿水平升高和氧化参数升高。我们的数据表明,DNX和ß1-肾上腺素受体拮抗剂-卡维地洛能有效减轻GN中的氧化应激、炎症、ER应激、自噬、铁变态反应和细胞凋亡。
{"title":"Carvedilol through ß1-Adrenoceptor blockade ameliorates glomerulonephritis via inhibition of oxidative stress, apoptosis, autophagy, ferroptosis, endoplasmic reticulum stress and inflammation","authors":"Wei-Yu Lin ,&nbsp;Yu-Hsuan Cheng ,&nbsp;Pei-Yu Liu ,&nbsp;Shih-Ping Hsu ,&nbsp;San-Chi Lin ,&nbsp;Chiang-Ting Chien","doi":"10.1016/j.bcp.2024.116570","DOIUrl":"10.1016/j.bcp.2024.116570","url":null,"abstract":"<div><div>Glomerulonephritis (GN) is one of the main causes of end stage renal disease and requires an effective treatment for inhibiting GN. Renal nerves through efferent (RENA) and afferent (RANA) innervation to glomeruli regulate the glomerular function. We delineated the role of RENA and RANA on anti-Thy1.1-induced GN. Female Wistar rats were divided into Control, Thy1.1 plus anti-Thy1.1, bilaterally renal nerve denervation (DNX) plus anti-Thy1.1, and topical capsaicin to bilateral renal nerves for selective ablation of RANA (DNAX) plus anti-Thy1.1. We examined RANA and RENA response to anti-Thy1.1 and compared the effect of DNX or DNAX on urinary oxidative stress, renal gp91, tyrosine hydroxylase (TH), calcitonin gene-related peptide (CGRP), apoptosis, autophagy, ferroptosis, antioxidant enzymes, endoplasmic reticulum (ER) stress and inflammation by western blot. Anti-Thy1.1 significantly enhanced RENA, but did not affect RANA. DNX significantly decreased TH and CGRP expression, whereas DNAX only reduced CGRP expression. Anti-Thy1.1 significantly increased glomerulosclerosis injury, urinary protein, electron paramagnetic resonance signals of alpha-(4-pyridyl-N-oxide)-N-<em>tert</em>-butylnitrone adducts, 8-isoprostane and nitrotyrosine levels, NADPH oxidase gp91phox (gp91), macrophage/monocyte (ED-1), GRP-78, Beclin-1/LC3-II, Bax/caspase-3/poly(ADP-ribose) polymerase expression, inflammatory cytokines levels and decreased renal Copper/Zinc superoxide dismutase, Cystine/glutamate transporter (xCT) and Glutathione peroxidase 4 (GPX4) expression vs. Control. The enhanced oxidative parameters or reduced antioxidant defense by anti-Thy1.1 were significantly attenuated by DNX but not DNAX. Additionally, oral ß1-adrenoceptor antagonist-Carvedilol at an early stage reduced anti-Thy1.1 increased proteinuria level and oxidative parameters. Our data suggest that DNX and ß1-adrenoceptor antagonist-Carvedilol efficiently attenuate oxidative stress, inflammation, ER stress, autophagy, ferroptosis and apoptosis in GN.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116570"},"PeriodicalIF":5.3,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ursodeoxycholic acid alleviates fat embolism syndrome-induced acute lung injury by inhibiting the p38 MAPK/NF-κB signalling pathway through FXR 熊去氧胆酸通过 FXR 抑制 p38 MAPK/NF-κB 信号通路,减轻脂肪栓塞综合征诱发的急性肺损伤。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-11 DOI: 10.1016/j.bcp.2024.116574
Xudong He , Jinye Shi , Lina Bu , Shuting Zhou , Kaixuan Wu , Gui Liang , Xiaotao Xu , Aizhong Wang
Acute lung injury (ALI) caused by fat embolism syndrome (FES) is a disease with high mortality. This study aimed to explore the roles of ursodeoxycholic acid (UDCA) in FES-induced ALI and its underlying mechanisms. An ALI mouse model was established by allografting mouse perinephric fat. For in vitro experiments, human pulmonary microvascular endothelial cells (HPMEC) were treated with FFAs. The effects of UDCA on the expression of farnesoid X receptor (FXR) and the inflammatory response in endothelial cells were investigated. UDCA significantly inhibited the inflammatory response and the expression of proinflammatory markers during FES-induced ALI. UDCA markedly decreased TNF-α and IL-1β expression in vitro. UDCA administration markedly upregulated FXR expression and significantly reduced the phosphorylation of p38 MAPK and NF-κB p65. Knock down FXR expression decreased the effect of UDCA in vivo. Furthermore, knock down FXR expression and overexpressing FXR increased and decreased the inflammatory response, respectively, in vitro. Moreover, administration of a p38 MAPK activator reversed the anti-inflammatory effect of FXR overexpression. UDCA ameliorated inflammation during FES-induced ALI by suppressing p38 MAPK/NF-κB signalling and activating FXR. These findings provide new evidence for the potential of UDCA for FES-induced ALI treatment.
脂肪栓塞综合征(FES)引起的急性肺损伤(ALI)是一种死亡率很高的疾病。本研究旨在探讨熊去氧胆酸(UDCA)在脂肪栓塞综合征诱发的急性肺损伤中的作用及其内在机制。通过异体移植小鼠肾周脂肪,建立了 ALI 小鼠模型。在体外实验中,用脂肪酸处理人肺微血管内皮细胞(HPMEC)。研究了 UDCA 对内皮细胞中法尼类固醇 X 受体(FXR)表达和炎症反应的影响。在 FES 诱导的 ALI 中,UDCA 能明显抑制炎症反应和促炎症标志物的表达。UDCA 可明显降低体外 TNF-α 和 IL-1β 的表达。服用 UDCA 能显著上调 FXR 的表达,并显著降低 p38 MAPK 和 NF-κB p65 的磷酸化。敲除 FXR 的表达会降低 UDCA 在体内的作用。此外,在体外敲除 FXR 表达和过表达 FXR 分别增加和减少了炎症反应。此外,服用 p38 MAPK 激活剂可逆转 FXR 过度表达的抗炎作用。UDCA 通过抑制 p38 MAPK/NF-κB 信号传导和激活 FXR 改善了 FES 诱导的 ALI 期间的炎症反应。这些发现为 UDCA 治疗 FES 诱导的 ALI 的潜力提供了新的证据。
{"title":"Ursodeoxycholic acid alleviates fat embolism syndrome-induced acute lung injury by inhibiting the p38 MAPK/NF-κB signalling pathway through FXR","authors":"Xudong He ,&nbsp;Jinye Shi ,&nbsp;Lina Bu ,&nbsp;Shuting Zhou ,&nbsp;Kaixuan Wu ,&nbsp;Gui Liang ,&nbsp;Xiaotao Xu ,&nbsp;Aizhong Wang","doi":"10.1016/j.bcp.2024.116574","DOIUrl":"10.1016/j.bcp.2024.116574","url":null,"abstract":"<div><div>Acute lung injury (ALI) caused by fat embolism syndrome (FES) is a disease with high mortality. This study aimed to explore the roles of ursodeoxycholic acid (UDCA) in FES-induced ALI and its underlying mechanisms. An ALI mouse model was established by allografting mouse perinephric fat. For in vitro experiments, human pulmonary microvascular endothelial cells (HPMEC) were treated with FFAs. The effects of UDCA on the expression of farnesoid X receptor (FXR) and the inflammatory response in endothelial cells were investigated. UDCA significantly inhibited the inflammatory response and the expression of proinflammatory markers during FES-induced ALI. UDCA markedly decreased TNF-α and IL-1β expression in vitro. UDCA administration markedly upregulated FXR expression and significantly reduced the phosphorylation of p38 MAPK and NF-κB p65. Knock down FXR expression decreased the effect of UDCA in vivo. Furthermore, knock down FXR expression and overexpressing FXR increased and decreased the inflammatory response, respectively, in vitro. Moreover, administration of a p38 MAPK activator reversed the anti-inflammatory effect of FXR overexpression. UDCA ameliorated inflammation during FES-induced ALI by suppressing p38 MAPK/NF-κB signalling and activating FXR. These findings provide new evidence for the potential of UDCA for FES-induced ALI treatment.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116574"},"PeriodicalIF":5.3,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intermediate conductance calcium-activated potassium channel (KCa3.1) in cancer: Emerging roles and therapeutic potentials 癌症中的中间传导钙激活钾通道(KCa3.1):新的作用和治疗潜力
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-11 DOI: 10.1016/j.bcp.2024.116573
Nhung Thi Hong Van , Joo Hyun Nam
The KCa3.1 channel (also known as the KCNN4, IK1, or SK4 channel) is an intermediate-conductance calcium-activated potassium channel that regulates the membrane potential and maintains calcium homeostasis. Recently, KCa3.1 channels have attracted increasing attention because of their diverse roles in various types of cancers. In cancer cells, KCa3.1 channels regulate key processes, including cell proliferation, cell cycle, migration, invasion, tumor microenvironments, and therapy resistance. In addition, abnormal KCa3.1 expression in cancers is utilized to distinguish between tumor and normal tissues, classify cancer stages, and predict patient survival outcomes. This review comprehensively examines the current understanding of the contribution of KCa3.1 channels to tumor formation, metastasis, and its mechanisms. We evaluated the potential of KCa3.1 as a biomarker for cancer diagnosis and prognosis. Finally, we discuss the advances and challenges of applying KCa3.1 modulators in cancer treatment and propose approaches to overcome these obstacles. In summary, this review highlights the importance of this ion channel as a potent therapeutic target and prognostic biomarker of cancer.
KCa3.1 通道(又称 KCNN4、IK1 或 SK4 通道)是一种中间传导性钙激活钾通道,可调节膜电位并维持钙平衡。最近,KCa3.1 通道因其在各类癌症中的不同作用而日益受到关注。在癌细胞中,KCa3.1 通道调控着细胞增殖、细胞周期、迁移、侵袭、肿瘤微环境和耐药性等关键过程。此外,癌症中 KCa3.1 的异常表达可用于区分肿瘤和正常组织、划分癌症分期以及预测患者的生存结果。这篇综述全面探讨了目前对 KCa3.1 通道对肿瘤形成、转移的贡献及其机制的理解。我们评估了 KCa3.1 作为癌症诊断和预后生物标志物的潜力。最后,我们讨论了在癌症治疗中应用 KCa3.1 调节剂的进展和挑战,并提出了克服这些障碍的方法。总之,本综述强调了该离子通道作为癌症的有效治疗靶点和预后生物标志物的重要性。
{"title":"Intermediate conductance calcium-activated potassium channel (KCa3.1) in cancer: Emerging roles and therapeutic potentials","authors":"Nhung Thi Hong Van ,&nbsp;Joo Hyun Nam","doi":"10.1016/j.bcp.2024.116573","DOIUrl":"10.1016/j.bcp.2024.116573","url":null,"abstract":"<div><div>The KCa3.1 channel (also known as the KCNN4, IK1, or SK4 channel) is an intermediate-conductance calcium-activated potassium channel that regulates the membrane potential and maintains calcium homeostasis. Recently, KCa3.1 channels have attracted increasing attention because of their diverse roles in various types of cancers. In cancer cells, KCa3.1 channels regulate key processes, including cell proliferation, cell cycle, migration, invasion, tumor microenvironments, and therapy resistance. In addition, abnormal KCa3.1 expression in cancers is utilized to distinguish between tumor and normal tissues, classify cancer stages, and predict patient survival outcomes. This review comprehensively examines the current understanding of the contribution of KCa3.1 channels to tumor formation, metastasis, and its mechanisms. We evaluated the potential of KCa3.1 as a biomarker for cancer diagnosis and prognosis. Finally, we discuss the advances and challenges of applying KCa3.1 modulators in cancer treatment and propose approaches to overcome these obstacles. In summary, this review highlights the importance of this ion channel as a potent therapeutic target and prognostic biomarker of cancer.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116573"},"PeriodicalIF":5.3,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omega-3 polyunsaturated fatty acids alleviate hyperuricemic nephropathy by inhibiting renal pyroptosis through GPR120 欧米伽-3 多不饱和脂肪酸通过 GPR120 抑制肾脏热蛋白沉积,从而缓解高尿酸血症肾病
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-11 DOI: 10.1016/j.bcp.2024.116575
Zhi Yang , Hao Li , Hong-yan Wu, Yi Zhou, Jing-xue Du, Zhang-xue Hu
Hyperuricemic nephropathy (HN) is characterized by increased serum uric acid levels that incite renal inflammation. While omega-3 polyunsaturated fatty acids (PUFAs) are known for their anti-inflammatory properties, their impact on HN remains unclear. This study explored the effects of omega-3 PUFAs, specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), on HN. Using a mouse model induced by adenine and potassium oxonate, we treated HN mice with DHA, EPA, or both for four weeks. The results showed that omega-3 PUFAs significantly reduced serum uric acid levels and improved kidney function, with DHA, EPA, and their combination showing similar efficacy. Transcriptome sequencing and further analysis revealed that these fatty acids alleviate renal pyroptosis by reducing key markers such as NOD-like receptor pyrin containing 3 (NLRP3), cleaved gasdermin-D, caspase-1, and interleukin-1β. To further investigate the underlying mechanism, we focused on G-protein coupled receptor 120 (GPR120), a receptor activated by DHA. The use of a GPR120 antagonist (AH7614) partially blocked DHA’s effects, while the agonist (TUG891) mimicked its anti-pyroptotic actions. Co-immunoprecipitation assays showed that DHA activates GPR120, leading to its internalization and interaction with β-arrestin2, ultimately inhibiting NLRP3 inflammasome formation and reducing inflammation. Overall, omega-3 PUFAs, particularly through GPR120 activation, appear to protect against renal inflammation in HN by modulating the NLRP3/caspase-1/GSDMD pathway.
高尿酸血症肾病(HN)的特点是血清尿酸水平升高,从而引发肾脏炎症。众所周知,ω-3 多不饱和脂肪酸(PUFA)具有抗炎特性,但它们对高尿酸血症肾病的影响仍不清楚。本研究探讨了欧米伽-3 多不饱和脂肪酸,特别是二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)对 HN 的影响。我们使用腺嘌呤和氧化钾诱导的小鼠模型,用 DHA、EPA 或两者治疗 HN 小鼠四周。结果表明,ω-3 PUFA 能显著降低血清尿酸水平并改善肾功能,其中 DHA、EPA 及其组合具有相似的疗效。转录组测序和进一步分析表明,这些脂肪酸通过减少关键标记物,如含NOD样受体吡咯啉3(NLRP3)、裂解的gasdermin-D、caspase-1和白细胞介素-1β,缓解了肾脏的脓毒症。为了进一步研究其潜在机制,我们重点研究了被 DHA 激活的 G 蛋白偶联受体 120(GPR120)。使用 GPR120 拮抗剂(AH7614)部分阻断了 DHA 的作用,而激动剂(TUG891)则模拟了其抗突眼作用。共免疫沉淀试验表明,DHA 能激活 GPR120,使其内化并与β-arrestin2 相互作用,最终抑制 NLRP3 炎症小体的形成并减轻炎症反应。总之,ω-3 PUFAs,尤其是通过激活 GPR120,似乎可以通过调节 NLRP3/caspase-1/GSDMD通路来保护 HN 肾脏免受炎症侵袭。
{"title":"Omega-3 polyunsaturated fatty acids alleviate hyperuricemic nephropathy by inhibiting renal pyroptosis through GPR120","authors":"Zhi Yang ,&nbsp;Hao Li ,&nbsp;Hong-yan Wu,&nbsp;Yi Zhou,&nbsp;Jing-xue Du,&nbsp;Zhang-xue Hu","doi":"10.1016/j.bcp.2024.116575","DOIUrl":"10.1016/j.bcp.2024.116575","url":null,"abstract":"<div><div>Hyperuricemic nephropathy (HN) is characterized by increased serum uric acid levels that incite renal inflammation. While omega-3 polyunsaturated fatty acids (PUFAs) are known for their anti-inflammatory properties, their impact on HN remains unclear. This study explored the effects of omega-3 PUFAs, specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), on HN. Using a mouse model induced by adenine and potassium oxonate, we treated HN mice with DHA, EPA, or both for four weeks. The results showed that omega-3 PUFAs significantly reduced serum uric acid levels and improved kidney function, with DHA, EPA, and their combination showing similar efficacy. Transcriptome sequencing and further analysis revealed that these fatty acids alleviate renal pyroptosis by reducing key markers such as NOD-like receptor pyrin containing 3 (NLRP3), cleaved gasdermin-D, caspase-1, and interleukin-1β. To further investigate the underlying mechanism, we focused on G-protein coupled receptor 120 (GPR120), a receptor activated by DHA. The use of a GPR120 antagonist (AH7614) partially blocked DHA’s effects, while the agonist (TUG891) mimicked its anti-pyroptotic actions. Co-immunoprecipitation assays showed that DHA activates GPR120, leading to its internalization and interaction with β-arrestin2, ultimately inhibiting NLRP3 inflammasome formation and reducing inflammation. Overall, omega-3 PUFAs, particularly through GPR120 activation, appear to protect against renal inflammation in HN by modulating the NLRP3/caspase-1/GSDMD pathway.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116575"},"PeriodicalIF":5.3,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MEK1/2 promote ROS production and deubiquitinate NLRP3 independent of ERK1/2 during NLRP3 inflammasome activation 在 NLRP3 炎症小体激活过程中,MEK1/2 可促进 ROS 生成,并独立于 ERK1/2 对 NLRP3 进行去泛素化处理
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-11 DOI: 10.1016/j.bcp.2024.116572
Hanwen Chen , Shujun Xie , Yichen Zhou , Lin Chen , Jian Xu , Jianting Cai
Inflammasomes are cytosolic supramolecular complexes that play a key role in the innate immune response. Overactivation of NLR family pyrin domain containing 3 (NLRP3) inflammasome leads to multiple diseases. Post-translational modifications (PTMs) are essential modulators of inflammasomes especially in activation phase. Here we found that MEK1/2 kinase activity was indispensable in NLRP3 inflammasome activation both in vitro and in vivo. Inhibition of MEK1/2 resulted in reactive oxygen species (ROS) scavenging and ubiquitination of NLRP3, which further blocked NLRP3 inflammasome activation. These effects were independent of ERK1/2, which were classic downstream of MEK1/2. These investigations proposed a mechanism that MEK1/2 regulated inflammation via non-transcriptional regulation of NLRP3 inflammasome and might help better understanding the effects and side-effects of MEK inhibitors in clinical use.
炎症小体是一种细胞膜超分子复合物,在先天性免疫反应中发挥着关键作用。NLR 家族含吡啶域 3(NLRP3)炎性体的过度激活会导致多种疾病。翻译后修饰(PTM)是炎性小体的重要调节因子,尤其是在激活阶段。在这里,我们发现MEK1/2激酶的活性在体外和体内激活NLRP3炎症小体的过程中都是不可或缺的。抑制 MEK1/2 可清除活性氧(ROS)并使 NLRP3 泛素化,从而进一步阻断 NLRP3 炎症小体的激活。这些作用与ERK1/2无关,而ERK1/2是MEK1/2的经典下游。这些研究提出了MEK1/2通过NLRP3炎性体的非转录调控来调节炎症的机制,可能有助于更好地理解临床使用的MEK抑制剂的作用和副作用。
{"title":"MEK1/2 promote ROS production and deubiquitinate NLRP3 independent of ERK1/2 during NLRP3 inflammasome activation","authors":"Hanwen Chen ,&nbsp;Shujun Xie ,&nbsp;Yichen Zhou ,&nbsp;Lin Chen ,&nbsp;Jian Xu ,&nbsp;Jianting Cai","doi":"10.1016/j.bcp.2024.116572","DOIUrl":"10.1016/j.bcp.2024.116572","url":null,"abstract":"<div><div>Inflammasomes are cytosolic supramolecular complexes that play a key role in the innate immune response. Overactivation of NLR family pyrin domain containing 3 (NLRP3) inflammasome leads to multiple diseases. Post-translational modifications (PTMs) are essential modulators of inflammasomes especially in activation phase. Here we found that MEK1/2 kinase activity was indispensable in NLRP3 inflammasome activation both <em>in vitro</em> and <em>in vivo</em>. Inhibition of MEK1/2 resulted in reactive oxygen species (ROS) scavenging and ubiquitination of NLRP3, which further blocked NLRP3 inflammasome activation. These effects were independent of ERK1/2, which were classic downstream of MEK1/2. These investigations proposed a mechanism that MEK1/2 regulated inflammation via non-transcriptional regulation of NLRP3 inflammasome and might help better understanding the effects and side-effects of MEK inhibitors in clinical use.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116572"},"PeriodicalIF":5.3,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline 单个 P450 物种功能特性的非加成性及其在饮酒对氯胺酮和阿米替林代谢影响中的表现。
IF 5.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-10 DOI: 10.1016/j.bcp.2024.116569
Kannapiran Ponraj , Kari A. Gaither , Dilip Kumar Singh , Nadezhda Davydova , Mengqi Zhao , Shaman Luo , Phillip Lazarus , Bhagwat Prasad , Dmitri R. Davydov
To explore functional interconnections between multiple P450 enzymes and their manifestation in alcohol-induced changes in drug metabolism, we implemented a high-throughput study of correlations between the composition of the P450 pool and the substrate saturation profiles (SSP) of amitriptyline and ketamine demethylation in a series of 23 individual human liver microsomes preparations from donors with a known history of alcohol consumption. The SSPs were approximated with linear combinations of three Michaelis-Menten equations with globally optimized KM (substrate affinity) values. This analysis revealed a strong correlation between the rate of ketamine metabolism and alcohol exposure. For both substrates, alcohol consumption caused a significant increase in the role of the low-affinity enzymes. The amplitudes of the kinetic components and the total rate were further analyzed for correlations with the abundance of 11 major P450 enzymes assessed by global proteomics. The maximal rate of metabolism of both substrates correlated with the abundance of CYP3A4, their predicted principal metabolizer. However, except for CYP2D6 and CYP2E1, responsible for the low-affinity metabolism of ketamine and amitriptyline, respectively, none of the other potent metabolizers of the drugs revealed a positive correlation. Instead, in the case of ketamine, we observed negative correlations with the abundances of CYP1A2, CYP2C9, and CYP3A5. For amitriptyline, the data suggest inhibitory effects of CYP1A2 and CYP2A6. Our results demonstrate the importance of functional interactions between multiple P450 species and their decisive role in the effects of alcohol exposure on drug metabolism.
为了探索多种 P450 酶之间的功能相互联系及其在酒精诱导的药物代谢变化中的表现,我们对 P450 池的组成与阿米替林和氯胺酮去甲基化底物饱和度曲线(SSP)之间的相关性进行了高通量研究,这些底物饱和度曲线来自一系列 23 个已知有饮酒史的供体的人类肝脏微粒体制备物。SSP近似于三个Michaelis-Menten方程的线性组合,并具有全局优化的KM(底物亲和力)值。分析结果表明,氯胺酮的代谢率与酒精暴露之间存在密切联系。对于两种底物,饮酒都会显著增加低亲和力酶的作用。研究人员进一步分析了动力学成分的振幅和总代谢率与通过全局蛋白质组学评估的 11 种主要 P450 酶的丰度之间的相关性。两种底物的最大代谢率与预测的主要代谢物 CYP3A4 的丰度相关。然而,除了分别负责氯胺酮和阿米替林低亲和性代谢的 CYP2D6 和 CYP2E1 外,这两种药物的其他强代谢物都没有显示出正相关性。相反,在氯胺酮中,我们观察到与 CYP1A2、CYP2C9 和 CYP3A5 的丰度呈负相关。对于阿米替林,数据表明其对 CYP1A2 和 CYP2A6 有抑制作用。我们的研究结果表明了多种 P450 之间功能性相互作用的重要性,以及它们在酒精暴露对药物代谢的影响中所起的决定性作用。
{"title":"Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline","authors":"Kannapiran Ponraj ,&nbsp;Kari A. Gaither ,&nbsp;Dilip Kumar Singh ,&nbsp;Nadezhda Davydova ,&nbsp;Mengqi Zhao ,&nbsp;Shaman Luo ,&nbsp;Phillip Lazarus ,&nbsp;Bhagwat Prasad ,&nbsp;Dmitri R. Davydov","doi":"10.1016/j.bcp.2024.116569","DOIUrl":"10.1016/j.bcp.2024.116569","url":null,"abstract":"<div><div>To explore functional interconnections between multiple P450 enzymes and their manifestation in alcohol-induced changes in drug metabolism, we implemented a high-throughput study of correlations between the composition of the P450 pool and the substrate saturation profiles (SSP) of amitriptyline and ketamine demethylation in a series of 23 individual human liver microsomes preparations from donors with a known history of alcohol consumption. The SSPs were approximated with linear combinations of three Michaelis-Menten equations with globally optimized <em>K</em><sub>M</sub> (substrate affinity) values. This analysis revealed a strong correlation between the rate of ketamine metabolism and alcohol exposure. For both substrates, alcohol consumption caused a significant increase in the role of the low-affinity enzymes. The amplitudes of the kinetic components and the total rate were further analyzed for correlations with the abundance of 11 major P450 enzymes assessed by global proteomics. The maximal rate of metabolism of both substrates correlated with the abundance of CYP3A4, their predicted principal metabolizer. However, except for CYP2D6 and CYP2E1, responsible for the low-affinity metabolism of ketamine and amitriptyline, respectively, none of the other potent metabolizers of the drugs revealed a positive correlation. Instead, in the case of ketamine, we observed negative correlations with the abundances of CYP1A2, CYP2C9, and CYP3A5. For amitriptyline, the data suggest inhibitory effects of CYP1A2 and CYP2A6. Our results demonstrate the importance of functional interactions between multiple P450 species and their decisive role in the effects of alcohol exposure on drug metabolism.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"230 ","pages":"Article 116569"},"PeriodicalIF":5.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142405981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biochemical pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1